The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 48 | 14.0x | 20.8x | Around median | |
Growth | 93 | 30.2% | 6.1% | Top tier | |
Quality | 88 | 38.0% | 6.6% | Top tier | |
Safety | 74 | 0.2x | 0.7x | Top tier | |
Capital Return | 29 | 0.00% | 2.02% | Bottom tier | |
Momentum | 8 | -37.6% | 4.1% | Bottom tier | |
Sentiment | 40 | 6 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
TransMedics Group, Inc. is an organ transplant technologies and services company, with a model centered on the OCS platform for warm perfusion organ preservation and the NOP model, which integrates clinical support with organ transport logistics. The company generates its revenue from transplant products associated with the OCS platform and from its services, including transport and logistics services dedicated to transplant procedures. In the first quarter of 2026, management said growth came from higher OCS case volumes, increased clinical adoption, and an expanding contribution from the integrated logistics platform.
In the first quarter of 2026, TransMedics recorded revenue of $173.9 million according to EDGAR data, compared with management’s reiterated annual guidance for 2026 revenue of between $727 million and $757 million, representing expected growth of between 20% and 25% above 2025. Gross profit was $101.2 million, and net income was $7.3 million, with earnings per share of $0.20 for the quarter. On a non-GAAP basis, the company reported adjusted operating income of approximately $18.1 million, equivalent to an adjusted operating margin of about 10.4% of revenue.
The first-quarter mix was closely tied to liver and heart transplantation and logistics: U.S. transplant revenue was about $167 million, including about $139 million for liver, $26 million for heart, and $2 million for lung. Product revenue was about $108 million, up 22% year over year and 8% sequentially, while service revenue was about $66 million, up 19% year over year and 9% sequentially. International revenue was also about $5.6 million, up 39% year over year and 17% sequentially, with a primary contribution from heart and a smaller contribution from lung.
The data show that the company’s market capitalization is approximately $2.5 billion, while the data source does not present a valid earnings multiple despite the company achieving positive net income in 2025 and the first quarter of 2026. Analyst consensus is Buy with an average price target of $116, with a target range between $80 and $142, so the live price shown outside this text should be compared with that target rather than fixing a price figure that may change. From a valuation perspective, the stock currently depends more on continued revenue growth of between 20% and 25% in 2026 and later margin improvement toward a gross target of about 60% than on a reported earnings multiple in the provided data.
Figures in the text are as of 2026-07-06; the live price is shown at the top of the page.
TransMedics sells the OCS platform for organ preservation and NOP services tied to clinical support and transplant logistics. In the first quarter of 2026, product revenue was about $108 million, while service revenue was about $66 million. The largest organ contribution came from liver in the United States at about $139 million, followed by heart revenue of about $26 million and lung revenue of about $2 million. This makes the company’s model a mix of medical devices, consumables or transplant products, and specialized logistics services.
CHOPS is the TransMedics Controlled Hypothermic Organ Preservation System, an active cooling device designed to provide temperatures between 4 and 12 degrees Celsius. The company unveiled it at the ISHLT conference in April 2026, and plans to submit an IDE supplement within weeks of the May 5, 2026 call. Management expects approval and implementation in early third quarter 2026, and also intends to submit a 510(k) application for commercial use in the United States. The company sees CHOPS as targeting DBD hearts with short preservation times, not as a replacement for current OCS uses.
ENHANCE and DENOVO are intended to expand the clinical evidence and adoption in heart and lung transplantation within the United States. Management said ENHANCE Part A is running slightly ahead of schedule, while Part B was delayed due to competitive confusion around the comparison arm. Introducing CHOPS as an option for the control arm could allow enrollment to be reactivated in early third quarter 2026 if the IDE supplement is approved. Management also said DENOVO is already enrolling a limited number of patients, and expects acceleration after the introduction of CHOPS.
Automated analysis for informational purposes only — not investment advice.
Liver was the largest driver, contributing about $139 million of U.S. transplant revenue during the first quarter of 2026. But the company also pointed to progress in heart, where U.S. revenue was about $26 million, and to a contribution from logistics, with transplant logistics service revenue of about $32 million. Total service revenue grew 19% year over year to about $66 million, reflecting higher use of the aviation and logistics platform. International revenue also grew 39% year over year to about $5.6 million, although it remained small compared with the U.S. market.
Management pointed to near-term margin pressure due to investments in inventory, DENOVO and ENHANCE, the NOP network, and international expansion. First-quarter gross margin was about 58%, down about 331 basis points year over year, while adjusted operating expenses rose 42% year over year to about $83 million. The company also discussed volatility in U.S. deceased donor volumes due to the National Transplant Modernization Act and its impact on OPOs. Even so, management kept 2026 revenue guidance at $727 million to $757 million.
International revenue remains small but is growing, reaching about $5.6 million in the first quarter of 2026, up 39% year over year and 17% sequentially. The company is building NOP infrastructure in Italy across 4 centers to cover northern and southern Italy. It is also engaging with parties in the Netherlands and Belgium to establish NOP centers with dedicated TransMedics clinical teams to manage OCS cases. In Europe, it signed an agreement with PAD Aviation in Germany to establish a dedicated air network for organ transplant logistics using Embraer Phenom 300Es.